PT  - JOURNAL ARTICLE
AU  - ALDO CAVALLINI
AU  - ANNA MARIA VALENTINI
AU  - CATIA LIPPOLIS
AU  - DANIELA CAMPANELLA
AU  - VITO GUERRA
AU  - MARIA LUCIA CARUSO
TI  - <em>KRAS</em> Genotyping as Biomarker in Colorectal Cancer: A Comparison of Three Commercial Kits on Histologic Material
DP  - 2010 Dec 01
TA  - Anticancer Research
PG  - 5251--5256
VI  - 30
IP  - 12
4099  - http://ar.iiarjournals.org/content/30/12/5251.short
4100  - http://ar.iiarjournals.org/content/30/12/5251.full
SO  - Anticancer Res2010 Dec 01; 30
AB  - Background/Aim: The crucial role of KRAS status in new colorectal cancer target therapy raises the issue regarding which testing method to use. This study analysed 112 formalin fixed, paraffin-embedded (FFPE) metastatic tissue samples using three different commercially available kits. Patients and Methods: A group of 40 KRAS wild-type (wt), 40 codon 12-mutated and 32 codon-13 mutated samples, previously evaluated by real-time PCR (TheraScreen kit), used as reference method, were analysed by Ampli-set-K-RAS and K-RAS StripAssay kit (herein called kit A and B, respectively) based on two different technologies. Results: The sensitivity of both kits was 92.5% for wt samples, 100% and 95.0% for kit A and B, respectively for samples mutated in codon 12. The specificity was 100% for both kits for all groups of samples. After a minor modification of the kit A method, its specificity reached 100%. Conclusion: of low cost and easy to use, kit A may be suitable for use in a routine diagnostic setting.